Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
THE family of Harshita Brella, a 24-year-old woman whose body was discovered in the boot of a car in east London earlier this month, has expressed their grief and love in a heartfelt tribute.
“Harshita, you left this world, but you are still with us in our hearts and will always be there,” the family said in a statement released through Northamptonshire police on Friday (22). “We will never forget you till our last breath. Always stay with us. We miss you in every moment of our life.”
Brella’s body was found in the early hours of 14 November in Ilford, east London. Investigators believe she was killed four days earlier, on 10 November, in Corby, Northamptonshire.
Her husband, 23-year-old Pankaj Lamba, has been named as the primary suspect, and police suspect he has fled the country.
Originally from India, Brella had moved to the UK in April after her arranged marriage to Lamba.
On Thursday (21), Northamptonshire police released CCTV footage showing the couple at Corby boating lake on the night of her suspected murder. Detectives have called for witnesses who may have seen the pair to come forward.
“Any information you have may help us piece together exactly what happened to Harshita and bring her killer to justice,” said DCI Johnny Campbell of the East Midlands special operations major crime unit.
Brella’s family, who reside in India, have voiced their dissatisfaction with the police response, alleging that authorities failed to protect her despite her complaints of domestic abuse weeks before her death.
“I believe the police did not do enough to help her or protect my sister,” said Brella’s elder sister, Sonia Dabas. “She reported her abuse, but the police processes just made her feel even more scared and alone. It drove her back to Pankaj.”
According to Northamptonshire police, Brella had been identified as a high-risk domestic abuse victim. Assistant chief constable Emma James said that Brella was assigned an independent domestic violence adviser and placed in a refuge.
Officers reportedly visited her multiple times, and her husband was arrested and bailed with conditions. A domestic violence protection order was granted by Northampton magistrates court on 5 September as investigations continued.
Following criticism of their handling of the case, Northamptonshire police have referred themselves to the Independent Office for Police Conduct. An internal domestic homicide review is also under way to examine the procedures followed during their interactions with Brella.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.